Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Avid Bioservices, Inc.    CDMO

AVID BIOSERVICES, INC.

(CDMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector news

AVID BIOSERVICES, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
06/30/2020 | 04:25pm EDT

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On June 30, 2020, Avid Bioservices, Inc. (the "Company") issued a press release to report the Company's financial results for the fourth quarter and fiscal year ended April 30, 2020. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. No additional information is included in this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed "filed" for purposes of, nor shall it be deemed incorporated by reference in, any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.


ITEM 7.01    REGULATION FD DISCLOSURE


On June 30, 2020, at 4:30 p.m. EDT/1:30 p.m. PDT, the Company will host a conference call to discuss its fourth quarter and fiscal year ended April 30, 2020 financial results. The webcast of the conference call will be archived on the Company's website for approximately 30 days.


ITEM 9.01    FINANCIAL STATEMENTS AND EXHIBITS


(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:



Exhibit

Number



99.1         Press Release issued June 30, 2020  .



  2

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
All news about AVID BIOSERVICES, INC.
09/15AVID BIOSERVICES, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fis..
AQ
09/15AVID BIOSERVICES : Announces Move to Virtual-Only Annual Meeting of Stockholders..
AQ
09/15Avid Bioservices Announces Move to Virtual-Only Annual Meeting of Stockholder..
GL
09/10AVID BIOSERVICES : to Participate in 18th Annual Morgan Stanley Global Healthcar..
AQ
09/10Avid Bioservices to Participate in 18th Annual Morgan Stanley Global Healthca..
GL
09/01AVID BIOSERVICES : Management's Discussion and Analysis of Financial Condition A..
AQ
09/01AVID BIOSERVICES, INC. : Results of Operations and Financial Condition, Regulati..
AQ
09/01AVID BIOSERVICES : Fiscal 1Q Earnings Snapshot
AQ
09/01Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2..
GL
08/31AVID BIOSERVICES, INC. : Other Events, Financial Statements and Exhibits (form 8..
AQ
More news
Financials (USD)
Sales 2021 80,9 M - -
Net income 2021 -3,11 M - -
Net Debt 2021 - - -
P/E ratio 2021 -136x
Yield 2021 -
Capitalization 425 M 425 M -
Capi. / Sales 2021 5,25x
Capi. / Sales 2022 4,22x
Nbr of Employees -
Free-Float 89,9%
Chart AVID BIOSERVICES, INC.
Duration : Period :
Avid Bioservices, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AVID BIOSERVICES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 11,00 $
Last Close Price 7,50 $
Spread / Highest target 46,7%
Spread / Average Target 46,7%
Spread / Lowest Target 46,7%
EPS Revisions
Managers
NameTitle
Nicholas S. Green President, Chief Executive Officer & Director
Joseph Carleone Non-Executive Chairman
Richard A. Richieri Chief Operating Officer
Daniel Ryan Hart Chief Financial Officer
Nick Ferguson Executive Director-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
AVID BIOSERVICES, INC.-2.22%425
CSL LIMITED7.60%94 696
BIOGEN INC.-7.90%43 264
SAMSUNG BIOLOGICS CO.,LTD.55.89%37 947
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.184.70%33 153
WUXI BIOLOGICS (CAYMAN) INC.79.73%31 073